Syndax Pharmaceuticals, Inc

(NASDAQ:SNDX)

Latest On Syndax Pharmaceuticals, Inc (SNDX):

Date/Time Type Description Signal Details
2023-05-09 04:24 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.59 beats by $0.01N/A
2023-05-09 04:24 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q1 2023 Earnings Call TranscriptN/A
2023-05-08 02:38 ESTNewsSyndax Pharmaceuticals Q1 2023 Earnings PreviewN/A
2023-03-04 02:40 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q4 2022 Earnings Call TranscriptN/A
2023-03-01 16:35 ESTNewsSyndax Pharmaceuticals: 2023 Is A Pivotal YearN/A
2023-03-01 01:25 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.62 beats by $0.04N/A
2023-02-27 19:50 ESTNewsSyndax Pharmaceuticals Q4 2022 Earnings PreviewN/A
2023-01-12 14:22 ESTNewsSyndax Pharmaceuticals (SNDX) Presents at the 41st Annual J.P. Morgan Healthcare Conference -- SlideshowN/A
2022-12-17 03:56 ESTNewsSyndax Pharmaceuticals (SNDX) Presents at 64th ASH Annual Meeting & ExpositionN/A
2022-12-12 19:48 ESTNewsKura Oncology falls, Syndax gains after Phase 1/2 data for leukemia candidatesN/A
2022-12-10 16:27 ESTNewsSyndax Pharmaceuticals: Today's Best Nearby Biotech Cap-Gain ProspectN/A
2022-12-07 20:58 ESTNewsSyndax Pharmaceuticals prices $150M offeringN/A
2022-12-07 01:27 ESTNewsSyndax Pharma to sell $150M stock in public offeringN/A
2022-12-05 14:27 ESTNewsSyndax receives breakthrough therapy tag for revumenib to treat acute leukemiaN/A
2022-11-06 14:31 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) Q3 2022 Earnings Call TranscriptN/A
2022-11-06 14:31 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q3 - Results - Earnings Call PresentationN/A
2022-11-04 08:33 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.58 beats by $0.07; updates FY22 guidanceN/A
2022-11-02 23:19 ESTNewsSyndax Pharmaceuticals Q3 2022 Earnings PreviewN/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q2 - Results - Earnings Call PresentationN/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.62N/A
2022-08-09 08:07 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q2 2022 Results - Earnings Call TranscriptN/A
2022-08-08 07:37 ESTNewsSyndax Pharmaceuticals Q2 2022 Earnings PreviewN/A
2022-06-13 12:56 ESTNewsKeith Goldan joins Syndax Pharmaceuticals as CFON/A
2022-05-10 14:01 ESTNewsSyndax Pharmaceuticals, Inc. 2022 Q1 - Results - Earnings Call PresentationN/A
2022-05-10 14:01 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q1 2022 Results - Earnings Call TranscriptN/A
2022-05-09 16:51 ESTNewsSyndax Pharmaceuticals GAAP EPS of -$0.63N/A
2022-05-09 00:26 ESTNewsSyndax Pharmaceuticals Q1 2022 Earnings PreviewN/A
2022-04-08 05:11 ESTNewsSyndax Pharmaceuticals: Cash-Rich With 2 Promising DrugsN/A
2022-03-25 00:25 ESTNewsSyndax Pharmaceuticals (SNDX) Presents At Barclays Global Healthcare ConferenceN/A
2022-03-02 06:49 ESTNewsSyndax appoints former Alnylam executive as new medical chiefN/A
2022-03-02 06:49 ESTNewsSyndax Pharmaceuticals GAAP EPS of $1.81 beats by $1.84, revenue of $126.6M beats by $67.92MN/A
2022-03-02 06:48 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Michael Metzger on Q4 2021 Results - Earnings Call TranscriptN/A
2022-02-28 18:56 ESTNewsSyndax Pharmaceuticals Q4 Earnings PreviewN/A
2022-01-29 06:36 ESTNewsSyndax Pharmaceuticals (SNDX) Investor Presentation - SlideshowN/A
2021-12-23 00:22 ESTNewsSyndax's SNDX-5613 an Orphan Drug in Europe for acute myeloid leukemiaN/A
2021-12-16 14:02 ESTNewsSyndax Pharma raises $75M via stock offeringN/A
2021-12-15 18:28 ESTNewsSyndax Pharmaceuticals drops 6% following underwritten stock offeringN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals EPS misses by $0.35, misses on revenueN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2021 Results - Earnings Call TranscriptN/A
2021-11-16 08:01 ESTNewsSyndax Pharmaceuticals, Inc. 2021 Q3 - Results - Earnings Call PresentationN/A
2021-11-14 18:13 ESTNewsSyndax Pharmaceuticals Q3 2021 Earnings PreviewN/A
2021-11-04 16:35 ESTNewsSyndax Pharma falls after updating early-stage data for leukemia therapyN/A
2021-10-05 15:59 ESTNewsSyndax Pharma CFO Daphne Karydas to resign to pursue another opportunityN/A
2021-09-28 02:06 ESTNewsIncyte and Syndax in pact for xatilimab targeting immune-related conditionsN/A
2021-08-10 12:01 ESTNewsSyndax Pharmaceuticals EPS beats by $0.28, beats on revenueN/A
2021-08-10 12:00 ESTNewsSyndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2021 Results - Earnings Call TranscriptN/A
2021-08-10 11:59 ESTNewsSyndax Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call PresentationN/A
2021-07-22 02:04 ESTNewsSyndax Pharmaceuticals: Updated Analysis After Reporting Interim Phase 1 DataN/A
2021-07-22 02:02 ESTNewsCanopy upgraded on economy reopening, Xeris PT cut on acquisition news, and more in analyst actionN/A
2021-07-22 01:35 ESTNewsSyndax shares rise on FDA Fast Track status for leukemia treatment SNDX-5613N/A

About Syndax Pharmaceuticals, Inc (SNDX):

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. The company was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

SNDX Quotes by TradingView

See Advanced Chart

General

  • Name Syndax Pharmaceuticals, Inc
  • Symbol SNDX
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 43
  • Fiscal Year EndDecember
  • IPO Date2016-03-03
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.syndax.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 634.74
  • Price/Book (Most Recent Quarter) 4.43
  • Enterprise Value Revenue 542.55
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$2.19
  • Next Year EPS Estimate -$2.17
  • Next Quarter EPS Estimate -$0.47
  • Operating Margin -4708%
  • Return on Assets -25%
  • Return on Equity -52%
  • Revenue 1.52 million
  • Earnings Per Share -$2.36
  • Revenue Per Share $0.04
  • Gross Profit 1.52 million
  • Quarterly Earnings Growth 0%
View More

Highlights

  • Market Capitalization 1.16 billion
  • EBITDA -67280000
  • PE Ratio -125.39
  • Analyst Target Price $32.14
  • Book Value Per Share $5.27
View More

Share Statistics

  • Shares Outstanding 48.24 million
  • Shares Float 42.95 million
  • % Held by Insiders 645%
  • % Held by Institutions 78.88%
  • Shares Short 4.93 million
  • Shares Short Prior Month 4.93 million
  • Short Ratio 9.27
  • Short % of Float 11%
  • Short % of Shares Outstanding 10%
View More

Technicals

  • Beta 1.84
  • 52 Week High $27.12
  • 52 Week Low $8.18
  • 50 Day Moving Average 22.33
  • 200 Day Moving Average 20.55
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Syndax Pharmaceuticals, Inc (SNDX) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Syndax Pharmaceuticals, Inc (SNDX) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-08$380000-$0.44-$0.5113.23%
2020-09-302020-11-02$N/A-$0.46-$0.43-6.75%
2020-06-302020-08-06$N/A-$0.42-$0.444.76%
2020-03-312020-05-07$379000-$0.56-$0.53-6.65%
2019-12-312020-03-03$380000-$0.44-$0.43-1.31%
2019-09-302019-11-07$379000-$0.41-$0.4813.92%
2019-06-302019-08-07$379000-$0.47-$0.470.76%
2019-03-312019-05-06$379000-$0.53-$0.554.14%
2018-12-312019-03-07$379000-$0.70-$0.64-9.43%
2018-09-302018-11-05$379000-$0.68-$0.7610.21%
2018-06-302018-08-07$379000-$0.74-$0.8916.94%
2018-03-312018-05-08$379000-$0.79-$0.9517.15%
2017-12-312018-03-05$1.19 million-$0.80-$0.77-3.67%
2017-09-302017-11-07$305000-$0.68-$0.8216.63%
2017-06-302017-08-10$305000-$0.70-$0.8214.83%
2017-03-312017-05-08$305000-$0.71-$0.710.56%
2016-12-312017-03-02$305000-$0.59-$0.7419.79%
2016-09-302016-11-10$305000-$0.84-$0.82-2.78%
2016-06-302016-08-09$305000-$0.47-$0.5412.18%
2016-03-312016-05-16$305000-$0.73-$0.48-52.22%

Syndax Pharmaceuticals, Inc (SNDX) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Syndax Pharmaceuticals, Inc (SNDX) Chart:

Syndax Pharmaceuticals, Inc (SNDX) News:

Below you will find a list of latest news for Syndax Pharmaceuticals, Inc (SNDX) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Syndax Pharmaceuticals, Inc (SNDX) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2025-06-202.50CALL0 00TRUE00
2025-06-2050CALL0 0206.3TRUE00
2025-06-207.53.22CALL0 2496.23TRUE00
2025-06-20101.5CALL0 58184.64TRUE00
2025-06-2012.50.4CALL0 70173.45FALSE00
2025-06-20150.1CALL0 16696.61FALSE00
2025-06-2017.50.1CALL1 9131.8FALSE0.10
2025-06-20200CALL0 0290.33FALSE00
2025-06-2022.50CALL0 0321.25FALSE00
2025-06-202.50PUT0 0334.82FALSE00
2025-06-2050PUT0 60186.87FALSE00
2025-06-207.50PUT0 7225.18FALSE00
2025-06-20100.5PUT0 237076.35FALSE00
2025-06-2012.50PUT0 4662.52TRUE00
2025-06-20150PUT0 75187.85TRUE00
2025-06-2017.50PUT0 0168.86TRUE00
2025-06-20200PUT0 0387.8TRUE00
2025-06-2022.50PUT0 0376.37TRUE00
2025-07-182.50CALL0 0934.65TRUE00
2025-07-1850CALL0 1323.39TRUE00
2025-07-187.50CALL0 099.25TRUE00
2025-07-18102CALL0 4192.41TRUE00
2025-07-1812.50.65CALL0 76863.99FALSE00
2025-07-18150.25CALL1 68876.35FALSE00
2025-07-1817.50.1CALL0 124688.39FALSE00
2025-07-18200.1CALL0 72586.32FALSE00
2025-07-1822.50CALL0 15233.87FALSE00
2025-07-18250CALL0 2290.09FALSE00
2025-07-18300CALL0 11259.86FALSE00
2025-07-182.50PUT0 0938.11FALSE00
2025-07-1850PUT0 0518.71FALSE00
2025-07-187.50PUT0 0311.91FALSE00
2025-07-18100.75PUT0 517077.31FALSE00
2025-07-1812.52PUT114 394677.54TRUE00
2025-07-18154.7PUT0 32881.56TRUE00
2025-07-1817.50PUT0 32688.68TRUE00
2025-07-18200PUT0 1697.95TRUE00
2025-07-1822.50PUT0 0197.65TRUE00
2025-07-18250PUT0 0127.13TRUE00
2025-07-18300PUT0 0258.58TRUE00
2025-10-172.50CALL0 0194.57TRUE00
2025-10-1750CALL0 0161.88TRUE00
2025-10-177.50CALL0 083.81TRUE00
2025-10-17103CALL0 9873.71TRUE00
2025-10-1712.51.75CALL1 6979.82FALSE0.10.06
2025-10-17151.15CALL0 554577.04FALSE00
2025-10-1717.50.58CALL0 16172.22FALSE00
2025-10-17200.42CALL0 24583.41FALSE00
2025-10-1722.50CALL0 089.44FALSE00
2025-10-17250.2CALL1 335681.89FALSE-0.02-0.09
2025-10-17300CALL0 0193.71FALSE00
2025-10-172.50PUT0 0799.31FALSE00
2025-10-1750PUT0 0301.24FALSE00
2025-10-177.50.7PUT0 35787.8FALSE00
2025-10-17101.65PUT0 43055.7FALSE00
2025-10-1712.53.2PUT0 963.12TRUE00
2025-10-17150PUT0 31075.57TRUE00
2025-10-1717.50PUT0 775.42TRUE00
2025-10-17200PUT0 098.87TRUE00
2025-10-1722.50PUT0 084.37TRUE00
2025-10-17250PUT0 0151.6TRUE00
2025-10-17300PUT0 098.65TRUE00
2026-01-162.50CALL0 1332.24TRUE00
2026-01-1650CALL0 077.23TRUE00
2026-01-167.50CALL0 2979.15TRUE00
2026-01-16103.5CALL0 4075.64TRUE00
2026-01-1612.52.45CALL4 10380.56FALSE2.450
2026-01-16151.25CALL0 3066.05FALSE00
2026-01-1617.50CALL0 56679.73FALSE00
2026-01-16200CALL0 39373.25FALSE00
2026-01-1622.50CALL0 5889.59FALSE00
2026-01-16250CALL0 9381.89FALSE00
2026-01-16300CALL0 2589.92FALSE00
2026-01-16350CALL0 893.85FALSE00
2026-01-162.50PUT0 0638.21FALSE00
2026-01-1650PUT0 5221.07FALSE00
2026-01-167.50PUT0 077.41FALSE00
2026-01-16101.98PUT0 1750.13FALSE00
2026-01-1612.50PUT0 1862.2TRUE00
2026-01-16150PUT0 21874.53TRUE00
2026-01-1617.50PUT0 15168.91TRUE00
2026-01-16200PUT0 093.7TRUE00
2026-01-1622.50PUT0 693.5TRUE00
2026-01-16250PUT0 0142.7TRUE00
2026-01-16300PUT0 0151.67TRUE00
2026-01-16350PUT0 0107.95TRUE00

Latest SNDX Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST3$15.6
Jun 13, 2022 7:59 PM EST4$15.6
Jun 13, 2022 7:59 PM EST1$15.6
Jun 13, 2022 7:59 PM EST100$15.61
Jun 13, 2022 7:59 PM EST45$15.61

Syndax Pharmaceuticals, Inc (SNDX) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020028764/0001564590-20-028764-index.htm
2019-09-05UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1395937/000000000019013216/0000000000-19-013216-index.htm
2019-02-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000021545719006549/0000215457-19-006549-index.htm
2020-02-06SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000083423720006818/0000834237-20-006818-index.htm
2020-09-09SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000083423720010194/0000834237-20-010194-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090221919000254/0000902219-19-000254-index.htm
2020-01-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090221920000308/0000902219-20-000308-index.htm
2019-04-08SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090266419001816/0000902664-19-001816-index.htm
2020-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000090266420000971/0000902664-20-000971-index.htm
2020-11-04SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000091957420006675/0000919574-20-006675-index.htm
2018-06-204Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000092189518001976/0000921895-18-001976-index.htm
2018-11-29SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189518003173/0000921895-18-003173-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189519000467/0000921895-19-000467-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000092189520000574/0000921895-20-000574-index.htm
2019-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000101359419000160/0001013594-19-000160-index.htm
2020-02-13SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000101359420000127/0001013594-20-000127-index.htm
2018-04-10DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000114036118018005/0001140361-18-018005-index.htm
2018-04-10DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1395937/000114036118018007/0001140361-18-018007-index.htm
2018-06-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312518197997/0001193125-18-197997-index.htm
2019-02-12SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312519034379/0001193125-19-034379-index.htm
2019-03-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519088951/0001193125-19-088951-index.htm
2019-03-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312519092679/0001193125-19-092679-index.htm
2019-03-29424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519092701/0001193125-19-092701-index.htm
2019-08-30S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1395937/000119312519235283/0001193125-19-235283-index.htm
2019-09-06CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1395937/000119312519239953/0001193125-19-239953-index.htm
2019-09-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312519242045/0001193125-19-242045-index.htm
2019-10-09SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312519265254/0001193125-19-265254-index.htm
2020-02-03424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000119312520022917/0001193125-20-022917-index.htm
2020-02-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000119312520023646/0001193125-20-023646-index.htm
2020-02-14SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312520037637/0001193125-20-037637-index.htm
2020-05-11SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1395937/000119312520139263/0001193125-20-139263-index.htm
2018-04-034Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002680/0001562180-18-002680-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002681/0001562180-18-002681-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002682/0001562180-18-002682-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002683/0001562180-18-002683-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002684/0001562180-18-002684-index.htm
2018-05-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018002685/0001562180-18-002685-index.htm
2018-09-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004047/0001562180-18-004047-index.htm
2018-09-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004048/0001562180-18-004048-index.htm
2018-09-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004049/0001562180-18-004049-index.htm
2018-09-274Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004050/0001562180-18-004050-index.htm
2018-11-074Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218018004443/0001562180-18-004443-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000852/0001562180-19-000852-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000853/0001562180-19-000853-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000854/0001562180-19-000854-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000855/0001562180-19-000855-index.htm
2019-02-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019000856/0001562180-19-000856-index.htm
2019-03-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2019-03-254/AStatement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002023/0001562180-19-002023-index.htm
2019-05-134Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003487/0001562180-19-003487-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003488/0001562180-19-003488-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003489/0001562180-19-003489-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003490/0001562180-19-003490-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003491/0001562180-19-003491-index.htm
2019-06-124Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003492/0001562180-19-003492-index.htm
2019-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019003880/0001562180-19-003880-index.htm
2019-10-114Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218019005140/0001562180-19-005140-index.htm
2020-02-054Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020000891/0001562180-20-000891-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001228/0001562180-20-001228-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001229/0001562180-20-001229-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001230/0001562180-20-001230-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001231/0001562180-20-001231-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001232/0001562180-20-001232-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001233/0001562180-20-001233-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001234/0001562180-20-001234-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001235/0001562180-20-001235-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001236/0001562180-20-001236-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001237/0001562180-20-001237-index.htm
2020-02-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020001238/0001562180-20-001238-index.htm
2020-07-084Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020005074/0001562180-20-005074-index.htm
2020-07-133Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020005102/0001562180-20-005102-index.htm
2020-11-064Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2018-03-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018004520/0001564590-18-004520-index.htm
2018-03-0810-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459018004911/0001564590-18-004911-index.htm
2018-05-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018011784/0001564590-18-011784-index.htm
2018-05-0910-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018012378/0001564590-18-012378-index.htm
2018-05-258-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018014349/0001564590-18-014349-index.htm
2018-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018019907/0001564590-18-019907-index.htm
2018-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018020483/0001564590-18-020483-index.htm
2018-08-08S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459018020504/0001564590-18-020504-index.htm
2018-09-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018023593/0001564590-18-023593-index.htm
2018-11-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459018026817/0001564590-18-026817-index.htm
2018-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459018026892/0001564590-18-026892-index.htm
2019-02-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019002676/0001564590-19-002676-index.htm
2019-03-0710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459019006772/0001564590-19-006772-index.htm
2019-03-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019006777/0001564590-19-006777-index.htm
2019-03-1810-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459019008313/0001564590-19-008313-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000156459019014263/0001564590-19-014263-index.htm
2019-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019015972/0001564590-19-015972-index.htm
2019-05-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019017318/0001564590-19-017318-index.htm
2019-06-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019022241/0001564590-19-022241-index.htm
2019-07-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019024625/0001564590-19-024625-index.htm
2019-08-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019030050/0001564590-19-030050-index.htm
2019-08-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019030067/0001564590-19-030067-index.htm
2019-08-07S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459019030084/0001564590-19-030084-index.htm
2019-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019036518/0001564590-19-036518-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019041712/0001564590-19-041712-index.htm
2019-11-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459019041719/0001564590-19-041719-index.htm
2019-12-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459019045581/0001564590-19-045581-index.htm
2020-02-108-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020004037/0001564590-20-004037-index.htm
2020-02-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020005551/0001564590-20-005551-index.htm
2020-03-038-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020008426/0001564590-20-008426-index.htm
2020-03-0510-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1395937/000156459020009016/0001564590-20-009016-index.htm
2020-04-29DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1395937/000156459020019694/0001564590-20-019694-index.htm
2020-04-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020019928/0001564590-20-019928-index.htm
2020-04-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020019941/0001564590-20-019941-index.htm
2020-05-04424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020020574/0001564590-20-020574-index.htm
2020-05-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020020633/0001564590-20-020633-index.htm
2020-05-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020022849/0001564590-20-022849-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020022971/0001564590-20-022971-index.htm
2020-06-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020028764/0001564590-20-028764-index.htm
2020-07-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020031882/0001564590-20-031882-index.htm
2020-08-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020037719/0001564590-20-037719-index.htm
2020-08-06S-8Securities to be offered to employees in employee benefit planshttps://www.sec.gov/Archives/edgar/data/1395937/000156459020037767/0001564590-20-037767-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020037777/0001564590-20-037777-index.htm
2020-11-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1395937/000156459020049638/0001564590-20-049638-index.htm
2020-11-0510-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1395937/000156459020051287/0001564590-20-051287-index.htm
2019-09-10EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1395937/999999999519002056/9999999995-19-002056-index.htm
2018-11-27CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999716026189/9999999997-16-026189-index.htm
2018-04-03CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718004150/9999999997-18-004150-index.htm
2018-06-13CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718006372/9999999997-18-006372-index.htm
2018-08-29CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718007508/9999999997-18-007508-index.htm
2018-12-20CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999718009113/9999999997-18-009113-index.htm
2019-03-28CT ORDERConfidential treatment orderhttps://www.sec.gov/Archives/edgar/data/1395937/999999999719002097/9999999997-19-002097-index.htm

Syndax Pharmaceuticals, Inc (SNDX) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Syndax Pharmaceuticals, Inc (SNDX). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 645%
Institutional Ownership: 7888%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2018-04-03Peter OrdentlichChief Scientific OfficerSell7,500.0015.00112,500.000.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm
2020-07-06Michael L. MeyersSVP, Chief Medical OfficerBuy3,500.0010,730.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020005074/0001562180-20-005074-index.htm
2020-11-04Michael A MetzgerPresident and COOBuy100,000.007.20720,000.00117,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2019-05-09Briggs MorrisonChief Executive OfficerBuy13,200.007.5699,726.0013,200.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2020-02-12Michael A MetzgerPresident and COOBuy15,000.0017,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020001238/0001562180-20-001238-index.htm
2020-11-04Michael A MetzgerPresident and COOSell100,000.0020.312,031,410.0017,659.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020006583/0001562180-20-006583-index.htm
2019-05-13Briggs MorrisonChief Executive OfficerBuy7,200.007.2952,516.8020,400.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002780/0001562180-19-002780-index.htm
2018-10-30Michael L. MeyersSVP, Chief Medical OfficerBuy200.004.79958.002,398.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018004443/0001562180-18-004443-index.htm
2019-10-10Briggs MorrisonChief Executive OfficerBuy11,000.005.4059,400.0031,400.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019005140/0001562180-19-005140-index.htm
2020-02-04Briggs MorrisonChief Executive OfficerBuy12,500.008.00100,000.0043,900.00https://www.sec.gov/Archives/edgar/data/1395937/000156218020000891/0001562180-20-000891-index.htm
2019-03-21Michael L. MeyersSVP, Chief Medical OfficerBuy1,000.004.934,930.007,118.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2019-03-21Michael L. MeyersSVP, Chief Medical OfficerBuy104.004.87506.487,222.00https://www.sec.gov/Archives/edgar/data/1395937/000156218019002012/0001562180-19-002012-index.htm
2018-04-03Peter OrdentlichChief Scientific OfficerBuy7,500.003.0823,100.007,500.00https://www.sec.gov/Archives/edgar/data/1395937/000156218018001800/0001562180-18-001800-index.htm